Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Q1 2025 Management View CEO Reshma Kewalramani highlighted $2.77 billion in revenue for Q1 2025, reflecting 3% growth compared to the prior year. The company focused on diversifying revenue through ...

Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of ...

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 results ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded rating to 'Buy.' Discover why!

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals ( VRTX 0.95%) on Casgevy. Although Vertex takes a ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue of $2.77 billion, up 3% year over year. In addition, Vertex revealed that ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management. The new campaign stars former NFL quarterback ...

Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Iovance Therapeutics' tumor-infiltrating lymphocyte therapies have tremendous ...